Could more caffeine help tiniest babies breathe easier?
NCT ID NCT07216365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a higher dose of caffeine citrate can improve breathing and reduce complications in extremely premature infants (born before 28 weeks). Forty babies will be randomly assigned to receive either a high or standard dose of caffeine, starting at one week old. Researchers will monitor oxygen levels, need for breathing support, and side effects to find the safest, most effective dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
caffeine citrate
What this could lead to
If successful, this study could establish a safer, more effective caffeine dose to help extremely premature babies breathe better and reduce serious complications like lung disease.
What could go wrong
This is a small, early-phase trial with only 40 infants, so results may not apply to all preemies. Higher caffeine doses could also cause side effects like rapid heart rate or high blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••